title: Targeted radionuclide therapies for pancreatic cancer.
abstract: Pancreatic malignancies, the fourth leading cause of cancer deaths, have an aggressive behavior with poor prognosis, resulting in a 5-year survival rate of only 4%. It is typically a silent malignancy until patients develop metastatic disease. Targeted radionuclide therapies of cancer such as radiolabeled peptides, which bind to the receptors overexpressed by cancer cells and radiolabeled antibodies to tumor-specific antigens provide a viable alternative to chemotherapy and external beam radiation of metastatic cancers. Multiple clinical trials of targeted radionuclide therapy of pancreatic cancer have been performed in the last decade and demonstrated safety and potential efficacy of radionuclide therapy for treatment of this formidable disease. Although a lot of progress has been made in treatment of pancreatic neuroendocrine tumors with radiolabeled (90)Y and (177)Lu somatostatin peptide analogs, pancreatic adenocarcinomas remain a major challenge. Novel approaches such as peptides and antibodies radiolabeled with alpha emitters, pre-targeting, bispecific antibodies and biological therapy based on the radioactive tumorlytic bacteria might offer a potential breakthrough in treatment of pancreatic adenocarcinomas.
authors.affiliation: Departments of Radiology, Albert Einstein College of Medicine, Bronx, NY, USA.
authors.forename: M
authors.initials: M
authors.lastname: Shah
authors.affiliation: Departments of Radiology, Albert Einstein College of Medicine, Bronx, NY, USA.
authors.forename: R
authors.initials: R
authors.lastname: Da Silva
authors.affiliation: Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, USA.
authors.forename: C
authors.initials: C
authors.lastname: Gravekamp
authors.affiliation: 1] Department of Surgery, Albert Einstein College of Medicine, Bronx, NY, USA [2] Department of Genetics, Albert Einstein College of Medicine, Bronx, NY, USA.
authors.forename: S K
authors.initials: SK
authors.lastname: Libutti
authors.affiliation: Departments of Radiology, Albert Einstein College of Medicine, Bronx, NY, USA.
authors.forename: T
authors.initials: T
authors.lastname: Abraham
authors.affiliation: 1] Departments of Radiology, Albert Einstein College of Medicine, Bronx, NY, USA [2] Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, USA.
authors.forename: E
authors.initials: E
authors.lastname: Dadachova
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology / Q000532:radiotherapy; D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000627:therapeutic use; D018278:Carcinoma, Neuroendocrine / Q000000981:diagnostic imaging / Q000473:pathology / Q000532:radiotherapy; D002986:Clinical Trials as Topic; D006801:Humans; D008087:Listeria / Q000737:chemistry; D058990:Molecular Targeted Therapy / Q000379:methods; D015282:Octreotide / Q000031:analogs & derivatives / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000627:therapeutic use; D010190:Pancreatic Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy*; D011868:Radioisotopes / Q000627:therapeutic use; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D012211:Rhenium / Q000627:therapeutic use
chemical_list: C539274:90Y-octreotate, DOTA(0)-Tyr(3)-Thr(8)-; D000911:Antibodies, Monoclonal; D009942:Organometallic Compounds; D011868:Radioisotopes; D019275:Radiopharmaceuticals; D012211:Rhenium; C447941:lutetium Lu 177 dotatate; C000589320:clivatuzumab; D015282:Octreotide